Skip to main content
Erschienen in: Endocrine 3/2022

13.10.2022 | Original Article

Accuracy of the intermittently scanned continuous glucose monitoring system in critically ill patients: a prospective, multicenter, observational study

verfasst von: Weifeng Huang, Siwan Li, Jingyi Lu, Yun Shen, Yaxin Wang, Yufei Wang, Kaixuan Feng, Xiaoli Huang, Yan Zou, Linjie Hu, Yihan Lu, Jian Zhou, Yingchuan Li

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

Continuous glucose monitoring (CGM) has the potential to improve glucose control in the intensive care unit (ICU) setting. We sought to evaluate the accuracy of the intermittently scanned CGM (isCGM) system in critically ill patients.

Research design and methods

Adult patients were consecutively enrolled from three ICUs from August 2020 to January 2021. The performance of FreeStyle Libre Pro was evaluated against the venous blood glucose samples as a reference. Numerical accuracy was examined by the mean absolute relative difference (MARD), the Bland–Altman analysis, and the International Organization for Standardization criteria. Clinical accuracy was assessed by performing the Clarke and consensus error grid analysis.

Results

A total of 122 patients were included and 3416 matched glucose pairs were analyzed. The overall MARD was 18.0%, and the highest MARD (33.1%) was observed in the hypoglycemic range (<70 mg/dL). The Bland–Altman analysis revealed a mean bias of −11.7 mg/dL, with the 95% limits of agreement of −73.0 to 49.5 mg/dL. The percentages of isCGM glucose values within ±15%/15, ±20%/20, and ±30%/30 mg/dL were 49.8%, 64.7%, and 84.5%, respectively. The Clarke and consensus error grid analysis showed acceptable clinical accuracy with 98.5% and 98.8% of glucose values falling into zones A and B.

Conclusions

Our study demonstrated suboptimal overall accuracy of isCGM for critically ill patients. Whether the adjunctive use of isCGM could improve glucose management and health outcomes in the critically ill needs further investigation.

Clinical trial registration

ChiCTR2100042036, Chinese Clinical Trial Registry.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat G. van den Berghe, P. Wouters, F. Weekers et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 345(19), 1359–1367 (2001)CrossRefPubMed G. van den Berghe, P. Wouters, F. Weekers et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 345(19), 1359–1367 (2001)CrossRefPubMed
2.
Zurück zum Zitat American Diabetes Association, 15. Diabetes care in the hospital: standards of medical care in diabetes—2021. Diabetes Care 44(Supplement 1), S211–S220 (2021)CrossRef American Diabetes Association, 15. Diabetes care in the hospital: standards of medical care in diabetes—2021. Diabetes Care 44(Supplement 1), S211–S220 (2021)CrossRef
3.
Zurück zum Zitat T. Danne, R. Nimri, T. Battelino et al. International consensus on use of continuous glucose monitoring. Diabetes Care 40(12), 1631–1640 (2017)CrossRefPubMedPubMedCentral T. Danne, R. Nimri, T. Battelino et al. International consensus on use of continuous glucose monitoring. Diabetes Care 40(12), 1631–1640 (2017)CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat R.W. Beck, T. Riddlesworth, K. Ruedy et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317(4), 371–378 (2017)CrossRefPubMed R.W. Beck, T. Riddlesworth, K. Ruedy et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317(4), 371–378 (2017)CrossRefPubMed
5.
Zurück zum Zitat R.A. Vigersky, S.J. Fonda, M. Chellappa et al. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 35(1), 32–38 (2012)CrossRefPubMed R.A. Vigersky, S.J. Fonda, M. Chellappa et al. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 35(1), 32–38 (2012)CrossRefPubMed
6.
Zurück zum Zitat A.M. Gómez, G.E. Umpierrez, O.M. Muñoz et al. Continuous glucose monitoring versus capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients hospitalized in the general ward and treated with a basal bolus insulin regimen. J. Diabetes Sci. Technol. 10(2), 325–329 (2015)CrossRefPubMedPubMedCentral A.M. Gómez, G.E. Umpierrez, O.M. Muñoz et al. Continuous glucose monitoring versus capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients hospitalized in the general ward and treated with a basal bolus insulin regimen. J. Diabetes Sci. Technol. 10(2), 325–329 (2015)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat S. Rijkenberg, S.C. van Steen, J.H. DeVries et al. Accuracy and reliability of a subcutaneous continuous glucose monitoring device in critically ill patients. J. Clin. Monit. Comput. 32(5), 953–964 (2018)CrossRefPubMed S. Rijkenberg, S.C. van Steen, J.H. DeVries et al. Accuracy and reliability of a subcutaneous continuous glucose monitoring device in critically ill patients. J. Clin. Monit. Comput. 32(5), 953–964 (2018)CrossRefPubMed
8.
Zurück zum Zitat P. Ancona, G.M. Eastwood, L. Lucchetta et al. The performance of flash glucose monitoring in critically ill patients with diabetes. Crit. Care Resusc. 19(2), 167–174 (2017)PubMed P. Ancona, G.M. Eastwood, L. Lucchetta et al. The performance of flash glucose monitoring in critically ill patients with diabetes. Crit. Care Resusc. 19(2), 167–174 (2017)PubMed
9.
Zurück zum Zitat F. Schierenbeck, A. Franco-Cereceda, J. Liska, Accuracy of 2 different continuous glucose monitoring systems in patients undergoing cardiac surgery. J. Diabetes Sci. Technol. 11(1), 108–116 (2017)CrossRefPubMed F. Schierenbeck, A. Franco-Cereceda, J. Liska, Accuracy of 2 different continuous glucose monitoring systems in patients undergoing cardiac surgery. J. Diabetes Sci. Technol. 11(1), 108–116 (2017)CrossRefPubMed
10.
Zurück zum Zitat E. Kotzapanagiotou, E. Tsotridou, E. Volakli et al. Evaluation of continuous flash glucose monitoring in a pediatric ICU setting. J. Clin. Monit. Comput. 34(4), 843–852 (2020)CrossRefPubMed E. Kotzapanagiotou, E. Tsotridou, E. Volakli et al. Evaluation of continuous flash glucose monitoring in a pediatric ICU setting. J. Clin. Monit. Comput. 34(4), 843–852 (2020)CrossRefPubMed
11.
Zurück zum Zitat M.C. Perez-Guzman, E. Duggan, S. Gibanica et al. Continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care 44(3), e50–e52 (2021)CrossRefPubMedPubMedCentral M.C. Perez-Guzman, E. Duggan, S. Gibanica et al. Continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care 44(3), e50–e52 (2021)CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Y. Zhang, X. Liu, J. Zhang et al. Evaluation for the feasibility and accuracy of Freestyle Libre Flash Glucose Monitoring System used by COVID-19 patients in intensive care unit. J. Diabetes 13(7), 603–605 (2021)CrossRefPubMed Y. Zhang, X. Liu, J. Zhang et al. Evaluation for the feasibility and accuracy of Freestyle Libre Flash Glucose Monitoring System used by COVID-19 patients in intensive care unit. J. Diabetes 13(7), 603–605 (2021)CrossRefPubMed
13.
Zurück zum Zitat D.C. Klonoff, J.L. Parkes, B.P. Kovatchev et al. Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care 41(8), 1681–1688 (2018)CrossRefPubMed D.C. Klonoff, J.L. Parkes, B.P. Kovatchev et al. Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care 41(8), 1681–1688 (2018)CrossRefPubMed
14.
Zurück zum Zitat M.J. Rice, J.L. Smith, D.B. Coursin, Glucose measurement in the ICU: regulatory intersects reality. Crit. Care Med. 45(4), 741–743 (2017)CrossRefPubMed M.J. Rice, J.L. Smith, D.B. Coursin, Glucose measurement in the ICU: regulatory intersects reality. Crit. Care Med. 45(4), 741–743 (2017)CrossRefPubMed
15.
Zurück zum Zitat V. Tyndall, R.H. Stimson, N.N. Zammitt et al. Marked improvement in HbA following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62(8), 1349–1356 (2019)CrossRefPubMedPubMedCentral V. Tyndall, R.H. Stimson, N.N. Zammitt et al. Marked improvement in HbA following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62(8), 1349–1356 (2019)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat M. Fokkert, P. van Dijk, M. Edens et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res. Care 7(1), e000809 (2019)CrossRefPubMedPubMedCentral M. Fokkert, P. van Dijk, M. Edens et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res. Care 7(1), e000809 (2019)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat S. Charleer, C. De Block, Van, L. Huffel et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 43(2), 389–397 (2020)CrossRefPubMed S. Charleer, C. De Block, Van, L. Huffel et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 43(2), 389–397 (2020)CrossRefPubMed
18.
Zurück zum Zitat J. Bolinder, R. Antuna, P. Geelhoed-Duijvestijn et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388(10057), 2254–2263 (2016)CrossRefPubMed J. Bolinder, R. Antuna, P. Geelhoed-Duijvestijn et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388(10057), 2254–2263 (2016)CrossRefPubMed
19.
Zurück zum Zitat J. Wernerman, T. Desaive, S. Finfer et al. Continuous glucose control in the ICU: report of a 2013 round table meeting. Crit. Care 18(3), 226 (2014)CrossRefPubMedPubMedCentral J. Wernerman, T. Desaive, S. Finfer et al. Continuous glucose control in the ICU: report of a 2013 round table meeting. Crit. Care 18(3), 226 (2014)CrossRefPubMedPubMedCentral
Metadaten
Titel
Accuracy of the intermittently scanned continuous glucose monitoring system in critically ill patients: a prospective, multicenter, observational study
verfasst von
Weifeng Huang
Siwan Li
Jingyi Lu
Yun Shen
Yaxin Wang
Yufei Wang
Kaixuan Feng
Xiaoli Huang
Yan Zou
Linjie Hu
Yihan Lu
Jian Zhou
Yingchuan Li
Publikationsdatum
13.10.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03216-3

Weitere Artikel der Ausgabe 3/2022

Endocrine 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.